The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or re…

Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCL+23 more

~Estimated

~$10 – $8,750

Schrödinger, Inc.NCT05544019

Phase 1

A Phase 1 Study of SynKIR-310, Autologous T Cells Transduced With CD19 KIR-CAR, in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administ…

B Cell LymphomaNHL, AdultMantle Cell Lymphoma+23 more

~Estimated

~$10 – $8,750

Verismo TherapeuticsNCT06544265